At the PAG conference, researchers said they are sequencing 100 tomato genomes in 100 days using Oxford Nanopore's PromethIon and a pipeline for maximizing SV diversity.
Fresh off its August IPO, the company reported $2.8 million in revenue for the quarter, up from $2.7 million a year ago.
Researchers explored the role of de novo variants and copy number alterations in the disease using new and existing exome sequences for children with Tourette disorder and their parents.
Using Hi-C, genome sequencing, and optical mapping, researchers profiled structural variants in multiple cancer cell lines, leading to potential non-coding drivers.
The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
One study characterized an allele linked to aggressive prostate cancer, while the other explored the range of structural variations within metastatic disease.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
Using Cancer Genome Atlas data, the researchers identified about 1,100 genes in a range of cancer types whose expression is disrupted by structural variants.
In Cell this week: structural variant profiles for metastatic prostate cancer; approach for visualizing mRNA, lncRNA transcription; and more.
Multi-Omics Factor Analysis looks for underlying causes of tumor variations by parsing and weighting genomic, epigenomic, transcriptomic, proteomic, and metabolomic data.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.